GLYCOMIMETICS INC (GLYC)

Get insights into the top gainers and losers of Friday's after-hours session.

Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.

GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024

GLYC Stock Earnings: GlycoMimetics Beats EPS for Q4 2023

GLYC stock results show that GlycoMimetics beat analyst estimates for earnings per share the fourth quarter of 2023.

GLYC Stock Earnings: GlycoMimetics Beats EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips GlycoMimetics (NASDAQ:GLYC) just reported results for the fourth quarter of 202...

GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023

GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024

GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference

GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia

GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference

GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023

Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board

/PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer,...

GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023

Tuesday Sector Leaders: Drugs, Biotechnology Stocks

GlycoMimetics chief medical officer Rock buys 65.4K shares (NASDAQ:GLYC)

GlycoMimetics' chief medical officer buys 65.4K shares, increasing holdings to 720.4K. No sales, 9.3% stock rise. Get the latest financial news.

GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687

GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference

GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023

GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023

GlycoMimetics joins Russell Microcap index (NASDAQ:GLYC)

GlycoMimetics (GLYC) has joined the Russell Microcap Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens on June 26, 2023

GlycoMimetics Announces Its Addition to the Russell Microcap® Index

GlycoMimetics Announces U.S. Food and Drug Administration Clears Addition of Time-based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia

GlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare Conference

GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023

GlycoMimetics to Report First Quarter 2023 Financial Results on May 3, 2023